Some patients with proteinase 3 specific anti-neutrophil cytoplasmic autoantibodies (PR3-ANCA) also have antibodies that react to complementary-PR3 (cPR3), a protein encoded by the antisense RNA of the PR3 gene. To study whether patients with anti-cPR3 antibodies have cPR3-responsive memory T cells we selected conditions that allowed cultivation of memory cells but not naïve cells. About half of the patients were found to have CD4 þ TH1 memory cells responsive to the cPR3 -peptide; while only a third of the patients had HI-PR3 protein responsive T cells. A significant number of T cells from patients responded to cPR3 138-169 peptide and to HI-PR3 protein by proliferation and/or secretion of IFN-c, compared to healthy controls while there was no response to scrambled peptide. Cells responsive to cPR3 -peptide were not detected in MPO-ANCA patients suggesting that this response is specific. The HLADRB1* 15 allele was significantly overrepresented in our patient group and is predicted to bind cPR3 138-169 peptide with high affinity. Regression analysis showed a significant likelihood that anti-cPR3 antibodies and cPR3-specific T cells coexist in individuals, consistent with an immunological history of encounter with a PR3-complementary protein.
Patients with antibodies reactive with our recombinant complementary proteinase 3 (cPR3 105À201 ) protein must have experienced an immunological encounter with a cPR3-like antigen. The following studies are based on the proposal that T cells involved in this immunological response remain in a memory cell pool and are identifiable.
Our investigations into complementary proteins in PR3-anti-neutrophil cytoplasmic autoantibody (ANCA) vasculitis disease began after some unexpected results during experiments designed to determine sites on PR3 protein recognized by PR3 autoantibodies. To generate bacterial clones expressing different fragments of human PR3 protein, a bluntended ligation strategy was used to clone randomly generated DNA fragments. Consequently, the DNA fragments could insert into the vector in either a sense or anti-sense orientation, and thus some bacterial clones were expressing a protein fragment from anti-sense RNA. Patients' sera were found to react to some of these cPR3-producing clones. Subsequently, a recombinant complementary PR3 protein was produced in a human cell line, termed cPR3 105À201 , which is the complement of the middle third of the sense PR3 protein (105-201 aa (amino acids)). Using this reagent, we proved that anti-cPR3 105À201 -specific antibodies were unique and that they bound PR3-ANCA to form an idiotypic pair. 1 
Furthermore, cPR3
105À201 protein and native PR3 physically interacted characteristic of a complementary protein pair.
Complementary proteins were first defined in the late 1960s by L.B. Mekler, 2, 3 who proposed that information embedded within the genetic code could identify proteins that would pair in nature, that is, proteins from sense codons bind proteins from their anti-sense codons. Many researchers have discovered protein partners by using complementary sequences coded by anti-sense codons (reviewed by Heal et al. 4 and Tropsha et al.
5
). Earlier studies focused on complementary proteins and their antibody-producing B cells. The present studies focus on T cells. To date, no one has purposefully searched in humans for T cells that respond to complementary protein counterparts of known autoantigens. What has been done in PR3-ANCA disease is a search for PR3-specific reactive T cells. Although a proliferative response was observed, the results failed to show a disease-specific association. [6] [7] [8] [9] [10] [11] [12] These data raise the question of why on the one hand we can identify disease-associated PR3 autoantibodies, 13 but on the other hand have difficulty identifying disease-associated T cells.
14 As a new approach, investigations into the potential contributions of complementary proteins could prove informative. In support, a report published in the year 2000 proposed that difficulties identifying disease-associated PR3-specific T cells could be explained if a protein complexed to PR3, and not PR3 itself, was what actually induced T cell help for PR3-specific B cells. 10 Could the protein suggested to be in complex with PR3 be a 'complementary protein'? It has been proposed that complementary proteins when complexed would have a unique structure that appears foreign. 15, 16 However, immunological responses incited by a complementary protein not complexed to its sense counterpart must be equally considered at this point.
If patients with PR3-ANCA have experienced an immunological encounter with a cPR3-like antigen, then the T cells involved in that encounter may still be present and identifiable. Herein we establish the first human correlate between T-cell responses and complementary proteins.
RESULTS

Patient study group
Patients with biopsy-proven PR3-ANCA vasculitis (n ¼ 30) were identified through the Glomerular Disease Collaborative Network between January 2004 and June 2006 (Table 1) .
All patients donated a blood sample were included in the study. However, if a patient's cells from a particular sample did not respond to recall antigens (a mixture of tetanus toxoid, diphtheria toxin, and Candida) was assumed anergic and was not included in that particular analysis. Thus, patient enrollment was generally limited to those in remission, slightly active disease on maintenance drugs, or newly diagnosed patients before aggressive treatment. Because of limitations on the amount of blood obtainable per donation, inclusion in the different analyses required that patients donate more than once during the study period (Table 1) .
Proliferative response of cPR3
138À169 peptide-reactive T cells
To test for T cells specific for cPR3, a peptide was synthesized (cPR3 ) containing 32 amino acids of the original recombinant protein (cPR3 105À201 ). This sequence was identified in epitope mapping studies as reactive with patients' antibodies, 1 and later confirmed by mass spectrometry (manuscript in review). Control peptides included scrambled amino acids of cPR3 138À169 and the sense counterpart of PR3 (sense PR3 138À169 ). A higher number of CD3 þ T cells from patients with PR3-ANCA (Wilcoxon ranked sum test, P ¼ 0.0014), but not patients with myeloperoxidase (MPO)-ANCA, proliferated upon encounter with cPR3
138À169 peptide compared with healthy controls (Figure 1b) . In parallel, patients were tested for T cells that proliferated in response to heat-inactivated full-length PR3 protein. An increase in proliferating cells was detected, although the majority of these were from four patients (P ¼ 0.01) (Figure 1c ). Cells from patients and healthy controls responded similarly to recall antigen stimulants (P ¼ 0.79). The percentage of background proliferation (% of total CD3 þ cells that were carboxyfluorescein diacetate succinimidyl ester (CFSE) dim ) was similar comparing patients (3.0±4.2%) and healthy controls (2.0±2.02%).
Proliferative response to cPR3 138À169 peptide occurred without additional co-stimulation with cytokines, suggesting that these T cells had a memory cell phenotype. 17 In support, KLH peptide, as a stimulant that requires naive cell proliferation, failed to produce a response using cells from 10 PR3-ANCA patients and 7 MPO-ANCA patients (mean CDI: recall antigens ¼ 6.55 ± 8.9; KLH ¼ 1.10 ± 0.49) (representative of data- Figure 1d ). We asked if the complex of peptides, cPR3 138-169 with sense PR3
138À169 , would have a differential effect on stimulating capacity. Eight patients' T-cell samples were examined for INF-g secretion in response to complexed peptides versus individual peptides. KLH peptide was included as a negative control. Rather than enhancing the INF-g response, mixing abrogated the cPR3 138À169 peptide effect ( Figure 3 ). Compiling the data from the proliferation and cytokine studies, a statistical analysis of people who respond to the various stimulants versus those who did not respond was determined based on the mean plus 2 s.d. of healthy controls setting Pp0.05 as significant ( Table 2 ). The analysis of the proliferation data indicated that a significant percentage of patients (54%) responded to cPR3 138À169 in contrast to the percentage of HI-PR3 protein responders (31%), which was not statistically different from healthy controls. Analysis of the INF-g data indicated that a significant number of patients responded to both cPR3 138À169 and HI-PR3 protein.
Specificity of responses to fragments of cPR3 138À169 peptide cPR3 138À169 peptide bears some homologies to a number of bacterial proteins. 1 It was questioned whether this 32 aa peptide had characteristics similar to a pathogenderived superagonist. Three 16 aa overlapping peptide fragments were tested for stimulatory characteristics with the supposition that superantigen-like sequences would bias reactivity toward one fragment. IFN-g responses were not restricted to only one sequence within a particular fragment (Table 3) , that is, no superantigen sequences were 18 indicated an overrepresentation of this allele in the patient group (Fisher's exact test, P ¼ 0.006) ( Table 4 ). There was no statistical differences for the alleles DQB1*6 (P ¼ 0.18), DQB1*5 (P ¼ 0.99), DQB1*3 (P ¼ 0.57), and DQB1*2 (P ¼ 0.26).
To address whether the DRB1*15 protein is a binder of cPR3 138À169 peptide, we performed an analysis using the Immune Epitope and Analysis Resource database. 19 HLA II molecules bind 8-aa fragments, and therefore the various alleles might preferentially bind different regions of the 32 aa cPR3 138À169 peptide. DRB1*01 and DRB1*15 bind with high affinity (IC 50 o50) ( Table 5) . DRB1*03, DRB1*07, DRB1*11, and DRB1*13 are predicted to bind with intermediate affinity, whereas DRB1*04 is the least likely to bind with a low affinity for only one region of the fragment.
Individual variability among longitudinal samples
The substantiation of the validity-specific T-cell responses in the patient group lies in the employment of multiple methodologies using repetitive patient samplings. A graphical representation of each patient's T-cell responsiveness overtime provides a look at the potential for variable outcomes (Figure 4a indicated an equal distribution within the responsive T-cell group and the non-responder group (Fisher's exact test P ¼ 0.99) (Figure 4b ). Other potential explanations such as type of medication (Table 1) or environmental-related factors were not identifiable. Variability is inevitable and appears to be a common occurrence in studies of human subjects. 10 Coexistence of cPR3-specific T cells with anti-cPR3-specific antibodies A critical question concerning the functional consequences of cPR3 138À169 peptide-reactive CD4 þ TH1 cells is whether they were involved in cPR3-specific B-cell maturation and antibody expression. To determine whether the patients enrolled in the T-cell study were positive anti-cPR3-specific antibodies, at any point during the course of their disease, all available-banked sera samples were screened. If a positive serum sample was identified for an individual, that individual was considered to have experienced an immunological response, which could be correlated with the 138-169 peptide-responsive cells as CD4 þ . Comparisons between groups were done using the Wilcoxon ranked sum test.
production of a memory T-cell pool. The mean value for patients was 27.96±21.20, compared with healthy controls at 15.59±5.51 (Wilcoxon ranked sum analysis, P ¼ 0.05). All patients with detectible antibodies were positive for reactive T cells (Figure 5a ). Because availability of sera samples was limited for some patients, a positive antibody episode may have been missed, so it is uncertain whether the remaining patients with positive for T cells ever had the antibodies. A ranked linear regression analysis indicated a likelihood of P-value of 0.0086 that, if patients had cPR3 138À169 peptide-reactive T cells, they would also have the reactive antibodies. The data support the conclusion that a complementary PR3 protein (or its mimic) was presented as a helper T-cell epitope stimulating B-cell maturation and antibody production.
DISCUSSION
This is the first report of disease-related T-cell responsiveness to a protein complementary to a known autoantigen. The data reveal cPR3 138À169 -responsive T cells of the CD4 þ -TH1 class, a T-cell subtype that is capable of delivering signals for B-cell maturation. 20 There was a significant correlation between the presence of anti-cPR3 antibodies and responsive T cells on an individual basis. These data are consistent with a complementary protein-specific component in immunological events of PR3-ANCA vasculitis autoimmune disease. Proliferation-based analyses of HI-PR3 protein responsiveness were significant when considering cell number, although the major contribution of positive cells was from only four patients and 4 of 13 responders did not reach significance, similar to published results. 10 However, HI-PR3 proteinresponsive T cells were found to have a positive correlation with disease, compared with healthy controls, as assessed using the IFN-g secretion assay. Nonetheless, the magnitude of the response was far below that seen in response to cPR3 138À169 . One explanation for the discordance of data between assays is that the ELISPOT assay can detect responses of fewer cells and thus is more sensitive.
The process that led to cPR3
138À169
-specific T cells, B cells, and antibodies required degradation of a complementary PR3 protein followed by the display of peptides by HLA class II molecules on the B-cell surface to T-helper cells. Genotyping HLA alleles of patients revealed that DRB1*15 is overrepresented in this group, and furthermore, DRB1*15 molecules are predicted to bind cPR3 138À169 peptide with high affinity (HLA Ligand/Motif Database). The HLA-DR2 (which includes DRB1*1501, DRB1*1502, DRB1*1601, and DRB1*1602) allele group has been associated with ANCA vasculitides in the past. [21] [22] [23] [24] Moreover, patients with DR2 were more likely to have persistently positive ANCA. HLA-DR2 has been associated also with multiple sclerosis, 25 anti-GBM disease, 26 and other chronic granulomatous diseases such as sarcoidosis 27 and leprosy. 28 An interesting case study reported a young boy homozygous for HLA-DR2 who developed anti-GBM disease coincident with ulcerative colitis. 29 It was proposed that the patient's homozygosity at HLA-DR2 was a predisposing factor for developing both diseases. We identified three patients who typed as DRB1*15 homozygosis and all three tested positive for cPR3 DRB1*0404) allele group has also been reported to have some associations with Wegener's vasculitis. 22, 30 What is particularly interesting about DR4 in our studies was that three of five patients who were negative for responses to cPR3 138À169 peptide were the DRB1*04 allele group and two of these have sinuslimited disease (the only two in the study). A number of other positive and negative associations with HLA genes have been reported in systemic vasculitis but what is clear is that there is yet to be a consensus of a consistent allelic association. [31] [32] [33] A limitation when studying human T cells is that the only available sample is peripheral blood cells, unlike animal studies where spleens and lymph nodes are available. Using circulating cells, we found that the number of spots in the ELISPOT assay were less than published animal studies using spleens. Others report similarly low numbers of spots from human peripheral cells and propose this is expected for lowfrequency reactive cells. 34 These are not unexpected as memory cells are thought to primarily reside in the spleen and peripheral lymphoid tissue, with low numbers of cells found in the circulation. Our efforts to expand the T cells in culture to increase the number of spots were unsuccessful. What is comforting is the degree of concordance between the proliferation studies and the ELISPOT assay with repetitive patient samplings. Even with these limitations, we The ELISPOT data are expressed as positive spots of treated wells minus spots on untreated wells. successfully demonstrated a strong statistically significant response in patients compared with healthy controls. A topic for discussion is why T cells specific for the PR3 autoantigen have been difficult to find at significant levels.
Clayton and Savage designed a system to determine whether PR3-specific B cells require T cell help to produce antibodies using peripheral blood lymphocytes culture system. Their conclusions were that B cells from patients produce PR3 antibodies through a T-cell-independent pathway or through some nonspecific B-cell stimulation. 35 Nonetheless, PR3-specific T cells are identifiable. Consider for a moment that anti-idiotypic antibody processes are involved in the generation of PR3-specific antibodies. This possibility was supported when mice immunized with cPR3 105À201 peptide developed not only anti-cPR3 105À201 antibodies but also antibodies that reacted with human-native PR3. These mouse anti-human PR3 antibodies produced a cytoplasmic-staining pattern on human neutrophils identical to that produced by patients' PR3-ANCA. Thus, in these mice, the derivation of the anti-human PR3-reactive antibody must have occurred through an anti-idiotypic response incited by human-specific complementary protein. 1 The anti-idiotypic process is initiated with a T-cell and B-cell response against a PR3 complementary protein. Antibodies can regulate each other by suppressing or augmenting the immune reaction in a manner that would perpetuate autoimmune disease. [36] [37] [38] An antibody is immunogenic by virtue of its non-germlineencoded antigen-binding site. B cells are known to spontaneously display endogenous V region peptides on their HLA class II molecules and activate CD4 þ T cells. 39, 40 Display of immunoglobulin-derived peptides (idiotopes) on APC HLA II molecules can occur by several routes. Monocytes and dendritic cells phagocytize antigen-antibody complexes bound to surface F c receptors, and they directly phagocytize soluble antibodies through routine environmental sampling. Host antibodies are then degraded and loaded onto HLA II molecules and displayed on the APC surface in a manner similar to foreign antigens. 41 Alternatively, B cells endocytose antigens that ligate to surface immunoglobulin (the B-cell receptor) and process these proteins for display on HLA II molecules. [42] [43] [44] How can this information be incorporated into understanding PR3-ANCA generation? Experimental evidence indicates that animals immunized with human complementary PR3 protein not only develop antibodies reactive with the immunogen, but also the development of human-specific PR3 antibodies. That has been observed in mice, 1 rabbits, and chickens (unpublished data). Similarly, a research group that studies La/sodium chloride-sodium citratein buffer (SSB)-specific autoantibodies associated with Sjogren's syndrome and systemic lupus erythematosus found that mice immunized with the autoantigen's complementary peptide counterpart elicited antibodies against the immunogen and anti-idiotypic antibodies that reacted with the sense autoantigen. 45 It has been demonstrated in multiple autoimmunity animal models that anti-idiotypes, raised against autoantibodies, induced anti-anti-idiotypes that possessed characteristics of the initial autoantibodies and caused disease after immunization. 46, 47 A crucial question is the source of the actual complementary PR3 proteins that triggered the immunological responses described here. Ongoing studies are addressing this by probing for proteins from patient material that react with our antibodies from rabbits immunized with complementary peptides. The possibilities remain that it could be carried in by a microbe with proteins homologous to the complementary protein 48, 49 or that patients aberrantly transcribe and translate it.
1 Somewhat encouraging, we have detected anti-sense transcripts in patients using an anti-sense-specific primer for the reverse transcriptase reaction and PCR. 1 Whether these transcripts are-or even can be-translated is unclear, although there are reports of translated anti-sense transcripts. 50 A recent review proposed that 'complementary proteins, which occur naturally, or result from cellular dysfunction, might be more common than recognized currently. This implies that the role of complementary proteins in autoimmunity merits increasing investigation.' 51 Understanding when and how complementary proteins initiate autoimmune disease will depend on discovering where these proteins come from. Nevertheless, there is enough evidence to warrant a closer look.
MATERIALS AND METHODS Patients
All subjects gave written informed consent and participated in the study according to the guidelines of the UNC Institutional Review Board (IRB no. 97-MED-44). Patients enrolled in the study with PR3-ANCA disease (n ¼ 30) included 11 females and 19 males; mean age of 50.3 years (26-79 years); 3 blacks, 25 Caucasians, and 2 others ( Table 1) . Mean of PR3-ANCA titers across samples was 53.9 (range: 3.2-170.0). Healthy controls were recruited on site for blood donations (n ¼ 34). The disease control group of seven MPO-ANCA patients included five females and two males, mean age of 45 years (21-65 years), 1 black, 5 Caucasians, and 1 Asian. Limits on the amount of blood obtainable per donation required that the different methodologies in this study be done in tandem. Thirteen of 30 patients donated blood more than once during the study's 2-year period. Studies for anti-cPR3 antibody reactivity required the use of banked sera samples. Healthy control sera were from approved kidney transplant donors (n ¼ 12).
Proteins and synthetic peptides Recombinant cPR3
105À201 protein was produced as previously described:
1 sequence: DAGLAARDESANVMWPAEEGDHGDIELLQ DLGWGVVGTHAAPAHGQALGAVGHWLVLLWQLDCGDGGTEV GWAAQLDEENVVQFVLRVVVVQKHLSHREVLLGGLLRPHVVGS EHHVHQALGYVPQAVRGRQHEAG.
Synthetic peptides from Alpha Diagnostic (San Antonio, TX, USA) were included as follows: Native PR3 (Wieslab AB, Lund, Sweden) was passed over an Extracti-Gel AffinityPak detergent-removing column (Pierce, Rockford, IL, USA) and heat-inactivated (1001C/10 min) 12 to linearize the protein. 
